Nanomedical Diagnostics, a San Diego, CA-based biotech company developing and commercializing bioelectronics for use in research and diagnostics, completed a $1.6m Series A financing.
The round was led by Serra Ventures.
Led by CEO Ross Bundy, Nanomedical Diagnostics combines expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create graphene biological field effect transistor (BioFET) products.
The company intends to use the funds for the commercial release of AGILE Research, its new label-free, quantitative, affordable research tool for small molecule and protein analysis and for investigational product evaluation and market clearance of AGILE Lyme.
AGILE Research is slated to launch early 2016 for research use only, and it is not intended for clinical diagnostics.
FinSMEs
13/10/2015